{"id":"cabazitaxel-androgen-deprivation-therapy","safety":{"commonSideEffects":[{"rate":"82","effect":"Neutropenia"},{"rate":"47","effect":"Anemia"},{"rate":"22","effect":"Thrombocytopenia"},{"rate":"47","effect":"Diarrhea"},{"rate":"34","effect":"Nausea"},{"rate":"40","effect":"Fatigue"},{"rate":"13","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabazitaxel is a taxane that binds to and stabilizes microtubules, disrupting cell division and inducing apoptosis in rapidly dividing cancer cells. When combined with androgen deprivation therapy (ADT), which blocks testosterone production or signaling, the regimen addresses both hormone-sensitive and hormone-resistant prostate cancer cells, improving overall survival in metastatic castration-resistant prostate cancer (mCRPC).","oneSentence":"Cabazitaxel is a microtubule-stabilizing chemotherapy combined with androgen deprivation therapy to suppress testosterone production, targeting castration-resistant prostate cancer through dual mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:39.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"}]},"trialDetails":[{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT01952223","phase":"PHASE3","title":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-12","conditions":"Adenocarcinoma of Prostate, Progression of Prostate Cancer","enrollment":761},{"nctId":"NCT01420250","phase":"PHASE1","title":"Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-09-22","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT01978873","phase":"PHASE3","title":"Efficacy Study Evaluating Chemotherapy in Prostate Cancer","status":"UNKNOWN","sponsor":"Örebro University, Sweden","startDate":"2012-11","conditions":"Prostate Cancer","enrollment":400},{"nctId":"NCT01531205","phase":"PHASE2","title":"Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Jevtana-Leuporelin"],"phase":"phase_3","status":"active","brandName":"Cabazitaxel + Androgen deprivation therapy","genericName":"Cabazitaxel + Androgen deprivation therapy","companyName":"Örebro University, Sweden","companyId":"rebro-university-sweden","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabazitaxel is a microtubule-stabilizing chemotherapy combined with androgen deprivation therapy to suppress testosterone production, targeting castration-resistant prostate cancer through dual mechanisms. Used for Metastatic castration-resistant prostate cancer (mCRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}